Resource id #3DrugId:1d00000010resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   

Drug ID: 1d00000010

Drug Name: Acarbose

Generic Names: Abacus | Abacus 50 | Acarb | Acarb (50 mg) | Acarex (25 mg) | Acarex (50 mg) | Acarwin | Acarwin 50 | Acraz | Asucrose | Asucrose (50mg) | Diabose | Diabose (50 mg) | Diadose | Discarb | Discarb (50 mg) | Disorb | Disorb (50 mg) | Glubose (25 mg) | Glubos | Glucar (25 mg) | Glucar (50mg) | Glucarb | Glucobay | Glucobay (100mg) | Glucobay (50 mg) | Glucobose | Gludase | HeboseHebose (50 mg) | K -Carb | K -Carb (50 mg) | Olcarbos | Olcarbos (50 mg) | Rebose | Rebose (50 mg) | Recarb | Recarb (50 mg) | Subase | Zebay-25 | Zebose | Prandase | Precose | Exforge

Category: Antidiabetics

Legal Status: Non Opioid Prescription only drug


Indication for Mother: Category B:
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Recommended Dose: The recommended dose is 25 milligrams thrice daily initially and gradually raised to 50 milligrams thrice daily. The maximum recommended dose for patients > 60 kg is 100 mg three times daily.

Recommended In: This medication is an oral alpha-glucosidase inhibitor, prescribed for type 2 diabetes with diet and exercise and in some countries for prediabetes. Acarbose works by slowing the action of certain chemicals that break down food to release glucose (sugar) into your blood.

Directions For Use: It comes in the form of 50 and 25 milligrams tablet to take by mouth, with food.

Storage: Store it at room temperature in a tight container. Protect from moisture.

Dosage Forms: Tablet |

Side Effects: Central Nervous System- Shakiness, dizziness or lightheadedness, nervousness or irritability, sudden changes in behavior or mood, headache, clumsy or jerky movements, confusion, seizures, loss of consciousness.

Gastrointestinal- Abdominal pain, nausea, loss of appetite, diarrhea, flatulence, extreme thirst, extreme hunger, dark urine and clay-colored stools.

Sin- Pale skin, allergic reactions such as rash, hives, redness.

Miscellaneous- Sweating, weakness, frequent urination, blurred vision, easy bruising, unusual bleeding (nose, mouth, vagina, or rectum).

In Case of Overdose: Unlike sulfonylureas or insulin, an overdose of Acarbose will not result in hypoglycemia. An overdose may result in transient increases in flatulence, diarrhea, and abdominal discomfort which shortly subside. In cases of overdosage the patient should not be given drinks or meals containing carbohydrates (polysaccharides, oligosaccharides and disaccharides) for the next 46 hours.

Avoid If: Caution should be exercised in patients with history of very high blood sugar levels, cirrhosis, or intestinal disease, any allergy, during pregnancy and breastfeeding.

Drug Interaction: Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Acarbose, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.

Patients Receiving Sulfonylureas or Insulin: Sulfonylurea agents or insulin may cause hypoglycemia. Acarbose given in combination with a sulfonylurea or insulin may cause a further lowering of blood glucose and may increase the potential for hypoglycemia. If hypoglycemia occurs, appropriate adjustments in the dosage of these agents should be made. Very rarely, individual cases of hypoglycemic shock have been reported in patients receiving Acarbose therapy in combination with sulfonylureas and/or insulin.

Intestinal adsorbents (for example, charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (for example, amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.

Acarbose has been shown to change the bioavailability of digoxin when they are coadministered, which may require digoxin dose adjustment.

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main